AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23047118 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9451 400 mg/day
Number of subjects: 41
Study 23047118 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9451 200 mg/day (genotype 1b)
Number of subjects: 41
Study 23047118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 19763813 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples' voluntary counseling and testing (CVCT)
Number of subjects: 1521
Study 19763813 — intervention group
Group type: COMPARATOR
Intervention: Individual voluntary counseling and testing (IVCT)
Number of subjects: 1521
Study 18466075 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (1 week)
Number of subjects: 30
Study 18466075 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (1 week)
Number of subjects: 30
Study 18466075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (single dose with levothyroxine)
Number of subjects: 30
Study 16567981 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR with PCV7
Number of subjects: 694
Study 16567981 — intervention group
Group type: COMPARATOR
Intervention: MMR without PCV7
Number of subjects: 694
Study 12696630 — intervention group
Group type: EXPERIMENTAL
Intervention: DSCG-chlorpheniramine
Number of subjects: 10
Study 12696630 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen
Number of subjects: 10
Study 12696630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 10
Study 11090557 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% IV saline
Number of subjects: 8
Study 11090557 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% IV saline
Number of subjects: 8
Study 11090557 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% oral saline
Number of subjects: 8
Study 11090557 — intervention group
Group type: COMPARATOR
Intervention: No rehydration treatment
Number of subjects: 8
Study 8937491 — intervention group
Group type: EXPERIMENTAL
Intervention: Single administration of DMDC at 200 mg/m2 (initial dose) increased to 450 mg/m2.
Number of subjects: 28
Study 8937491 — intervention group
Group type: EXPERIMENTAL
Intervention: Single repeated administration of DMDC at 300 mg/m2.
Number of subjects: 28
Study 8937491 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-consecutive-day administration of DMDC starting at 30 mg/m2/day increased to 40 mg/m2/day.
Number of subjects: 28
Study 8937491 — intervention group
Group type: EXPERIMENTAL
Intervention: All administration schedules of DMDC.
Number of subjects: 28
Study 1530174 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (75 micrograms), followed by an infusion of 18.75 micrograms/h
Number of subjects: 24
Study 1530174 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 24
Study 1530174 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24
Study 3888116 — intervention group
Group type: EXPERIMENTAL
Intervention: MCNU
Number of subjects: 95
Study 3888116 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 95
Study 30679141 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle-tracking echocardiography (STE) analysis in DMD group
Number of subjects: 108
Study 30679141 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional echocardiographic measures
Number of subjects: 108
Study 30679141 — intervention group
Group type: EXPERIMENTAL
Intervention: Age effect on global LV longitudinal strain
Number of subjects: 108
Study 30679141 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular function
Number of subjects: 108
Study 30602630 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste (TP)
Number of subjects: 60
Study 30602630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash (MW)
Number of subjects: 60
Study 27083443 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab with FOLFOX4
Number of subjects: 951
Study 27083443 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab with FOLFIRI
Number of subjects: 951
Study 27083443 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab with best supportive care
Number of subjects: 951
Study 27083443 — intervention group
Group type: COMPARATOR
Intervention: Worst skin toxicity grade <3
Number of subjects: 951
Study 27083443 — intervention group
Group type: COMPARATOR
Intervention: Worst skin toxicity grade ≥3
Number of subjects: 951
Study 24870697 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 10
Study 24870697 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 10
Study 24870697 — intervention group
Group type: EXPERIMENTAL
Intervention: HFM (high-energy, high-fat meal)
Number of subjects: 10
Study 24870697 — intervention group
Group type: EXPERIMENTAL
Intervention: HFM
Number of subjects: 10
Study 22103692 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for living themes identified from qualitative interviews
Number of subjects: 36
Study 20513886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral subvastus approach with tibial tubercle osteotomy
Number of subjects: 32
Study 20513886 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar approach
Number of subjects: 32
Study 17673455 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen sperm from cryptozoospermic patients
Number of subjects: 116
Study 17673455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh sperm from cryptozoospermic patients
Number of subjects: 116
Study 17673455 — intervention group
Group type: COMPARATOR
Intervention: Fresh sperm from control group (normal patients >10(5) spermatozoa/ml)
Number of subjects: 116
Study 17673455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh sperm from oligospermic patients
Number of subjects: 116
Study 15876629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal analysis of body motion
Number of subjects: 0
Study 15876629 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly subjects
Number of subjects: 0
Study 11192874 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐378 200 mg with ritonavir 100 mg every 12 h plus stavudine 40 mg and lamivudine 150 mg every 12 h (group I)
Number of subjects: 100
Study 11192874 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐378 400 mg with ritonavir 100 or 200 mg plus stavudine and lamivudine every 12 h (group II)
Number of subjects: 100
Study 9626825 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (adjunctive therapy)
Number of subjects: 3289
Study 9626825 — intervention group
Group type: COMPARATOR
Intervention: Heparin (adjunctive therapy)
Number of subjects: 3289
Study 8066221 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamete intrafallopian transfer (GIFT)
Number of subjects: 0
Study 8066221 — intervention group
Group type: COMPARATOR
Intervention: In vitro fertilization (IVF)
Number of subjects: 0
Study 8066221 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdrop insemination
Number of subjects: 0
Study 8066221 — intervention group
Group type: COMPARATOR
Intervention: Subzonal sperm microinjection (SUSM)
Number of subjects: 0
Study 8066221 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate transfer of SUSM oocytes to the Fallopian tube
Number of subjects: 0
Study 8066221 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct microinjection of epididymal sperm from azoospermic men
Number of subjects: 0
Study 3057956 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary oral nutrition for 3 months (Group 1)
Number of subjects: 14
Study 3057956 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diet for 9 months (Group 2)
Number of subjects: 14
Study 3057956 — intervention group
Group type: COMPARATOR
Intervention: Normal diet for 9 months (Group 3 - Control)
Number of subjects: 14
Study 29463619 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct aspiration first pass (ADAPT) approach
Number of subjects: 0
Study 29463619 — intervention group
Group type: COMPARATOR
Intervention: Stent retriever as the first-line (SRFL) approach
Number of subjects: 0
Study 28734660 — intervention group
Group type: EXPERIMENTAL
Intervention: CAN/AML combination therapy (8 mg/5 mg)
Number of subjects: 425
Study 28734660 — intervention group
Group type: EXPERIMENTAL
Intervention: CAN/AML combination therapy (16 mg/5 mg)
Number of subjects: 425
Study 28734660 — intervention group
Group type: EXPERIMENTAL
Intervention: CAN/AML combination therapy (16 mg/10 mg)
Number of subjects: 425
Study 28734660 — intervention group
Group type: COMPARATOR
Intervention: CAN (8 mg)
Number of subjects: 425
Study 28734660 — intervention group
Group type: COMPARATOR
Intervention: AML (10 mg)
Number of subjects: 425
Study 28734660 — intervention group
Group type: COMPARATOR
Intervention: AML (5 mg)
Number of subjects: 425
Study 26239766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (titrated up to 3.0mg/d over 15 days)
Number of subjects: 0
Study 26239766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23477485 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 123
Study 21368745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresolimumab (up to 4 mg/kg)
Number of subjects: 16
Study 19047525 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression defined as a Center for Epidemiological Studies Depression score of 16 or higher
Number of subjects: 2088
Study 17725138 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (liquid diet within 8 hours, soft diet next meal, regular diet thereafter)
Number of subjects: 200
Study 17725138 — intervention group
Group type: COMPARATOR
Intervention: Conventional feeding (no mouth feeding for first 24 hours, liquid diet on first postoperative day, soft diet on second postoperative day)
Number of subjects: 200
Study 17725138 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 200
Study 17725138 — intervention group
Group type: COMPARATOR
Intervention: Conventional feeding
Number of subjects: 200
Study 14571754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 500 mg every 12 h
Number of subjects: 53
Study 14571754 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefotaxime 2 g every 8 h
Number of subjects: 53
Study 14571754 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone 2 g every 24 h
Number of subjects: 53
Study 14571754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 53
Study 16202717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering diet from gestational week 17 to 20 to birth
Number of subjects: 290
Study 16202717 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 290
Study 10599355 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 41
Study 10599355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 7492038 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine as a standing-order medication
Number of subjects: 239
Study 7492038 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical controls from 1992)
Number of subjects: 239
Study 1664617 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotyline
Number of subjects: 93
Study 1664617 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 93
Study 7021071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1600 mg, 400 mg every 6 hours)
Number of subjects: 30
Study 7021071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28662676 — intervention group
Group type: COMPARATOR
Intervention: Yogurt smoothie with no BB‐12® (YS)
Number of subjects: 30
Study 28662676 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB‐12® added pre‐fermentation (PRE)
Number of subjects: 30
Study 28662676 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB‐12® added post‐fermentation (POST)
Number of subjects: 30
Study 28662676 — intervention group
Group type: EXPERIMENTAL
Intervention: BB‐12® containing capsule (CAP)
Number of subjects: 30
Study 25037968 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied from the first day of the conditioning regimen until day 7 post-HSCT
Number of subjects: 30
Study 25037968 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 30
Study 25037968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 30
Study 23895803 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 4330
Study 23895803 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 4330
Study 23895803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4330
Study 20942831 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab + interferon-α2a (IFN)
Number of subjects: 649
Study 20942831 — intervention group
Group type: COMPARATOR
Intervention: IFN + placebo
Number of subjects: 649
Study 20942831 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab + IFN (censored for TKIs)
Number of subjects: 649
Study 20942831 — intervention group
Group type: COMPARATOR
Intervention: IFN + placebo (censored for TKIs)
Number of subjects: 649
Study 19364976 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 portion of fruit and vegetables daily
Number of subjects: 117
Study 19364976 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 portions of fruit and vegetables daily
Number of subjects: 117
Study 19364976 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 portions of fruit and vegetables daily
Number of subjects: 117
Study 19364976 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 portion per day during run-in)
Number of subjects: 117
Study 17485711 — intervention group
Group type: EXPERIMENTAL
Intervention: SLND + ALND
Number of subjects: 891
Study 17485711 — intervention group
Group type: COMPARATOR
Intervention: SLND alone
Number of subjects: 891
Study 15598756 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from any health care professional
Number of subjects: 37
Study 15598756 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians
Number of subjects: 37
Study 15598756 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiprovider teams
Number of subjects: 37
Study 15598756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentists
Number of subjects: 37
Study 15598756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 37
Study 15598756 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study 11464225 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg elemental Cu/day as CuSO4
Number of subjects: 16
Study 11464225 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg elemental Cu/day as CuSO4
Number of subjects: 16
Study 11464225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9579817 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with isolated aortic stenosis (AS)
Number of subjects: 39
Study 7995323 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ramipril
Number of subjects: 24
Study 7995323 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with piretanide
Number of subjects: 24
Study 7995323 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with ramipril
Number of subjects: 24
Study 7995323 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg piretanide
Number of subjects: 24
Study 7995323 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of ramipril and piretanide
Number of subjects: 24
Study 3376144 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 ml/kg)
Number of subjects: 0
Study 3376144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31364885 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 31364885 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 0
Study 30665722 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT-301 (levodopa inhalation powder)
Number of subjects: 0
Study 30665722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29143588 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25873249 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive total gastrectomy
Number of subjects: 168
Study 25873249 — intervention group
Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 168
Study 24061990 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT-TP (Intensity-Modulated Radiation Therapy plus chemotherapy with docetaxel and cisplatin)
Number of subjects: 170
Study 24061990 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT-TP
Number of subjects: 170
Study 24061990 — intervention group
Group type: COMPARATOR
Intervention: IMRT (Simple Intensity-Modulated Radiation Therapy)
Number of subjects: 170
Study 21960694 — intervention group
Group type: EXPERIMENTAL
Intervention: Common polymorphisms in ADIPOQ (rs266729, rs182052, rs822391, rs2082940)
Number of subjects: 2553
Study 21960694 — intervention group
Group type: EXPERIMENTAL
Intervention: Common polymorphisms in ADIPOQ (rs266729, rs182052, rs16861209, rs17366568, rs3774261, rs7639352)
Number of subjects: 2553
Study 21960694 — intervention group
Group type: EXPERIMENTAL
Intervention: Common polymorphisms in ADIPOQ (rs1686109, rs17366568, rs3774261)
Number of subjects: 2553
Study 21960694 — intervention group
Group type: EXPERIMENTAL
Intervention: Common polymorphism in ADIPOQ (rs16861205)
Number of subjects: 2553
Study 21960694 — intervention group
Group type: COMPARATOR
Intervention: 16 variants in ADIPOR1/R2
Number of subjects: 2553
Study 21110393 — intervention group
Group type: EXPERIMENTAL
Intervention: Judicial directions provided before the child complainant testified
Number of subjects: 130
Study 21110393 — intervention group
Group type: COMPARATOR
Intervention: Endorsement of CSA misconceptions
Number of subjects: 130
Study 18265636 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper abdominal surgery (transversal laparotomy, elliptic periumbilical laparotomy, upper midline laparotomy, transrectal laparotomy, subcostal laparotomy)
Number of subjects: 105
Study 18265636 — intervention group
Group type: COMPARATOR
Intervention: Low abdominal surgery (low midline laparotomy, inguinal incision)
Number of subjects: 105
Study 15996667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion with arithmetic increase
Number of subjects: 120
Study 15996667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion with geometric increase
Number of subjects: 120
Study 12086732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release Ibifen (200 mg)
Number of subjects: 12
Study 12086732 — intervention group
Group type: COMPARATOR
Intervention: Orudis retard (200 mg)
Number of subjects: 12
Study 12086732 — intervention group
Group type: COMPARATOR
Intervention: Prompt release Ibifen (100 mg, two 12-h doses)
Number of subjects: 12
Study 9864078 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (mean daily dose: 3,646.15 mg)
Number of subjects: 13
Study 9864078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8666093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg loading dose, followed by 200 mg o.d.)
Number of subjects: 808
Study 8666093 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin-clavulanic acid (500/125 mg t.i.d.)
Number of subjects: 808
Study 8666093 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (1 g b.i.d.)
Number of subjects: 808
Study 8666093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 808
Study 8666093 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin-clavulanic acid
Number of subjects: 808
Study 8666093 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 808
Study 2355095 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 36
Study 2355095 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 36
Study 2355095 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridol
Number of subjects: 36
Study 2355095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 374454 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free (LF) drink
Number of subjects: 87
Study 374454 — intervention group
Group type: COMPARATOR
Intervention: Lactose-containing (LC) drink (4.5% lactose)
Number of subjects: 87
Study 374454 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath hydrogen analysis
Number of subjects: 87
Study 374454 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbers and malabsorbers
Number of subjects: 87
Study 31647257 — intervention group
Group type: EXPERIMENTAL
Intervention: Family interaction tasks (3 increasingly conflictual tasks)
Number of subjects: 458
Study 30767826 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Treatment (HIT)
Number of subjects: 686
Study 30767826 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Treatment (LIT)
Number of subjects: 686
Study 28498975 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 325
Study 25691671 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-B (bevacizumab 15 mg/kg every 3 weeks + endocrine therapy)
Number of subjects: 374
Study 25691671 — intervention group
Group type: COMPARATOR
Intervention: ET (letrozole or fulvestrant)
Number of subjects: 374
Study 23888538 — intervention group
Group type: EXPERIMENTAL
Intervention: Online coaching programme
Number of subjects: 44
Study 23888538 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 21453880 — intervention group
Group type: EXPERIMENTAL
Intervention: Probio‐Tec AB‐25 (Lactobacillus acidophilus La‐5 and Bifidobacterium animalis subsp. lactis BB‐12)
Number of subjects: 32
Study 21453880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21453880 — intervention group
Group type: EXPERIMENTAL
Intervention: Probio‐Tec AB‐25
Number of subjects: 32
Study 19661810 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16 therapeutic vaccine
Number of subjects: 35
Study 16729400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 379